OmniAb vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

OmniAb Inc. (OABI)

Q3 20267 Aug – 28 Aug 2026

▲4

OmniAb's revenue jump, raised guidance, and Lilly deal boost cash outlook

Q2 revenue surges 243%, loss narrows, guidance raised OmniAb's second-quarter revenue jumped to $13.4 million from $3.9 million a year earlier, and its net loss shrank to $5.9 million from $15.9 million. Management raised full-year 2026 revenue guidance to $32–36 million. This shows the business is growing and losing less money, which supports a higher stock price.
This is the core financial result that directly improves OABI's earnings outlook and investor confidence.
Eli Lilly ion channel deal adds up to $370M in milestones OmniAb signed a global collaboration with Eli Lilly for an ion channel program. OmniAb gets an upfront payment and could receive up to $370 million in milestone payments plus royalties on sales. This validates OmniAb's technology and brings in cash without selling new shares, which is good for the stock.
The Lilly deal is a major new partnership that boosts OmniAb's cash and credibility, directly affecting its valuation.
Cash forecast raised to $49–53 million on licensing deals OmniAb now expects to end 2026 with $49–53 million in cash, up from a prior $37–41 million estimate, thanks to recent licensing deals including Lilly. More cash means the company can fund operations longer without needing to raise money by selling stock, which reduces risk for shareholders.
The higher cash outlook directly addresses funding concerns and lowers the risk of dilution, a key driver for a small biotech stock.
New partner agreements with Argenx and Rosa Therapeutics OmniAb signed new agreements with Argenx and Rosa Therapeutics, adding to its 110 active partners and 425 active programs. Growing demand for its antibody discovery platforms shows the business can keep attracting partners, which supports future milestone revenue and stock price.
New partnerships signal growing platform demand, a key long-term growth driver for OmniAb.

August 20267 Aug – 28 Aug 2026

▲4

OmniAb's revenue jump, raised guidance, and Lilly deal boost cash outlook

Q2 revenue surges 243%, loss narrows, guidance raised OmniAb's second-quarter revenue jumped to $13.4 million from $3.9 million a year earlier, and its net loss shrank to $5.9 million from $15.9 million. Management raised full-year 2026 revenue guidance to $32–36 million. This shows the business is growing and losing less money, which supports a higher stock price.
This is the core financial result that directly improves OABI's earnings outlook and investor confidence.
Eli Lilly ion channel deal adds up to $370M in milestones OmniAb signed a global collaboration with Eli Lilly for an ion channel program. OmniAb gets an upfront payment and could receive up to $370 million in milestone payments plus royalties on sales. This validates OmniAb's technology and brings in cash without selling new shares, which is good for the stock.
The Lilly deal is a major new partnership that boosts OmniAb's cash and credibility, directly affecting its valuation.
Cash forecast raised to $49–53 million on licensing deals OmniAb now expects to end 2026 with $49–53 million in cash, up from a prior $37–41 million estimate, thanks to recent licensing deals including Lilly. More cash means the company can fund operations longer without needing to raise money by selling stock, which reduces risk for shareholders.
The higher cash outlook directly addresses funding concerns and lowers the risk of dilution, a key driver for a small biotech stock.
New partner agreements with Argenx and Rosa Therapeutics OmniAb signed new agreements with Argenx and Rosa Therapeutics, adding to its 110 active partners and 425 active programs. Growing demand for its antibody discovery platforms shows the business can keep attracting partners, which supports future milestone revenue and stock price.
New partnerships signal growing platform demand, a key long-term growth driver for OmniAb.

Latest7 Aug – 28 Aug 2026

▲4

OmniAb's revenue jump, raised guidance, and Lilly deal boost cash outlook

Q2 revenue surges 243%, loss narrows, guidance raised OmniAb's second-quarter revenue jumped to $13.4 million from $3.9 million a year earlier, and its net loss shrank to $5.9 million from $15.9 million. Management raised full-year 2026 revenue guidance to $32–36 million. This shows the business is growing and losing less money, which supports a higher stock price.
This is the core financial result that directly improves OABI's earnings outlook and investor confidence.
Eli Lilly ion channel deal adds up to $370M in milestones OmniAb signed a global collaboration with Eli Lilly for an ion channel program. OmniAb gets an upfront payment and could receive up to $370 million in milestone payments plus royalties on sales. This validates OmniAb's technology and brings in cash without selling new shares, which is good for the stock.
The Lilly deal is a major new partnership that boosts OmniAb's cash and credibility, directly affecting its valuation.
Cash forecast raised to $49–53 million on licensing deals OmniAb now expects to end 2026 with $49–53 million in cash, up from a prior $37–41 million estimate, thanks to recent licensing deals including Lilly. More cash means the company can fund operations longer without needing to raise money by selling stock, which reduces risk for shareholders.
The higher cash outlook directly addresses funding concerns and lowers the risk of dilution, a key driver for a small biotech stock.
New partner agreements with Argenx and Rosa Therapeutics OmniAb signed new agreements with Argenx and Rosa Therapeutics, adding to its 110 active partners and 425 active programs. Growing demand for its antibody discovery platforms shows the business can keep attracting partners, which supports future milestone revenue and stock price.
New partnerships signal growing platform demand, a key long-term growth driver for OmniAb.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.